Alban, Tyler J.
Chan, Timothy A.
Article History
First Online: 16 March 2021
Competing interests
: T.A.C. is a co-founder and holds equity in Gritstone Oncology; holds equity in An2H; acknowledges grant funding from and has been an advisor for An2H, AstraZeneca, Bristol–Myers Squibb, Eisai, Illumina and Pfizer; has been an advisor for MedImmune; and holds ownership of intellectual property on using tumour mutation burden to predict immunotherapy response, with a patent pending, which has been licensed to PGDx. T.J.A. declares no competing interests.